Jennison Associates LLC Apellis Pharmaceuticals, Inc. Transaction History

Jennison Associates LLC

$155 Billion
Q2 2024

A detailed history of Jennison Associates LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 3,591,416 shares of APLS stock, worth $101 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

3,591,416

Previous 3,240,513 10.83%

Holding current value

$101 Million

Previous $190 Million 27.67%

% of portfolio

0.09%

Previous 0.13%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$38.07 - $59.71 $13.4 Million - $21 Million	350,903 Added 10.83%	3,591,416 $138 Million
Q1 2024 May 02, 2024	SELL	$55.39 - $72.47 $1.96 Million - $2.57 Million	-35,409 Reduced 1.08%	3,240,513 $190 Million
Q4 2023 Feb 01, 2024	SELL	$37.14 - $64.82 $9.89 Million - $17.3 Million	-266,287 Reduced 7.52%	3,275,922 $196 Million
Q3 2023 Oct 31, 2023	BUY	$23.65 - $89.22 $37.2 Million - $140 Million	1,571,606 Added 79.75%	3,542,209 $135 Million
Q2 2023 Aug 03, 2023	SELL	$76.68 - $93.31 $49.2 Million - $59.9 Million	-642,164 Reduced 24.58%	1,970,603 $180 Million
Q1 2023 Apr 26, 2023	BUY	$46.59 - $66.96 $4.54 Million - $6.53 Million	97,450 Added 3.87%	2,612,767 $172 Million
Q4 2022 Feb 09, 2023	SELL	$43.24 - $61.04 $838,639 - $1.18 Million	-19,395 Reduced 0.77%	2,515,317 $130 Million
Q3 2022 Nov 01, 2022	BUY	$44.76 - $69.66 $10.6 Million - $16.5 Million	236,365 Added 10.28%	2,534,712 $173 Million
Q2 2022 Aug 02, 2022	SELL	$35.07 - $59.21 $14.2 Million - $24 Million	-406,043 Reduced 15.01%	2,298,347 $104 Million
Q1 2022 May 11, 2022	BUY	$35.46 - $54.12 $29.9 Million - $45.6 Million	842,233 Added 45.23%	2,704,390 $137 Million
Q4 2021 Feb 08, 2022	SELL	$30.74 - $49.16 $6.66 Million - $10.7 Million	-216,688 Reduced 10.42%	1,862,157 $88 Million
Q3 2021 Nov 09, 2021	SELL	$31.4 - $69.84 $11.6 Million - $25.9 Million	-370,679 Reduced 15.13%	2,078,845 $68.5 Million
Q2 2021 Aug 12, 2021	SELL	$40.9 - $64.9 $10.7 Million - $17 Million	-261,353 Reduced 9.64%	2,449,524 $155 Million
Q1 2021 May 11, 2021	SELL	$40.8 - $57.39 $2.51 Million - $3.53 Million	-61,543 Reduced 2.22%	2,710,877 $116 Million
Q4 2020 Feb 05, 2021	SELL	$30.79 - $57.2 $2.01 Million - $3.74 Million	-65,366 Reduced 2.3%	2,772,420 $159 Million
Q3 2020 Nov 04, 2020	BUY	$25.89 - $33.65 $18.4 Million - $23.9 Million	710,708 Added 33.41%	2,837,786 $85.6 Million
Q2 2020 Aug 06, 2020	BUY	$24.8 - $38.49 $931,512 - $1.45 Million	37,561 Added 1.8%	2,127,078 $69.5 Million
Q1 2020 May 06, 2020	BUY	$17.91 - $44.33 $17.6 Million - $43.6 Million	984,486 Added 89.09%	2,089,517 $56 Million
Q4 2019 Feb 07, 2020	BUY	$22.1 - $30.8 $147,539 - $205,620	6,676 Added 0.61%	1,105,031 $33.8 Million
Q3 2019 Nov 08, 2019	BUY	$24.09 - $32.18 $4.22 Million - $5.64 Million	175,111 Added 18.97%	1,098,355 $26.5 Million
Q2 2019 Aug 06, 2019	BUY	$18.0 - $25.34 $6.05 Million - $8.51 Million	335,863 Added 57.18%	923,244 $0
Q1 2019 May 10, 2019	BUY	$12.81 - $19.82 $5,854 - $9,057	457 Added 0.08%	587,381 $11.5 Million
Q4 2018 Feb 06, 2019	BUY	$11.47 - $18.71 $138,385 - $225,736	12,065 Added 2.1%	586,924 $7.74 Million
Q3 2018 Nov 08, 2018	BUY	$16.57 - $21.03 $72,825 - $92,426	4,395 Added 0.77%	574,859 $10.2 Million
Q2 2018 Aug 02, 2018	BUY	$19.63 - $30.0 $3.76 Million - $5.74 Million	191,313 Added 50.46%	570,464 $12.6 Million
Q1 2018 Apr 20, 2018	SELL	$14.01 - $26.02 $3.19 Million - $5.93 Million	-227,774 Reduced 37.53%	379,151 $8.38 Million
Q4 2017 Jan 25, 2018	BUY	$12.71 - $21.7 $7.71 Million - $13.2 Million	606,925	606,925 $13.2 Million

Others Institutions Holding APLS

# of Institutions

299

Shares Held

113M

Call Options Held

5.21M

Put Options Held

691K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.08B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.

Account

Jennison Associates LLC Apellis Pharmaceuticals, Inc. Transaction History